-
1 month ago | 
jamanetwork.com | Stefan Anker |Campus Virchow Klinikum |Tim Friede |Javed Butler
Visual Abstract. Efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency Figure 1. Recruitment, Randomization, and Follow-Up in the FAIR-HF2 Trial FAIR-HF2 indicates Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality. aThe precise reasons are unknown.
-
1 month ago | 
nature.com | Stefan Anker |Javed Butler |Frank Rockhold |Christian Röver |Marius Placzek
AbstractUncertainty remains about the effect of intravenous (IV) iron on outcomes for heart failure (HF) with iron deficiency. Here, we summarize the efficacy and safety of IV iron from six trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEART-FID, and FAIR-HF2) including 7,175 patients. In comparison to prior analyses, this meta-analysis adds new data from FAIR-HF2, uses a harmonized and robust Bayesian approach, and includes individual participant data from 5 trials.
-
2 months ago | 
onlinelibrary.wiley.com | Milton Packer |Javed Butler |Baylor Scott
Invited Editorial The win ratio for trials for heart failure: academic desperation or investigator decadence? Milton Packer, Corresponding Author Milton Packer Baylor University Medical Center, Dallas, TX, USA Imperial College, London, UK Corresponding author. Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 North Hall Street, Dallas, TX 75226, USA.
-
Jan 28, 2025 | 
onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott
Introduction Iron deficiency (ID) is known to impair mitochondrial energy production and cause adverse cardiac remodelling leading to left ventricular dysfunction.1-4 ID is prevalent in up to 50% of patients with heart failure (HF) and is an independently associated with worse functional status, symptoms, and cardiovascular outcomes irrespective of anaemia.5, 6 The FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure) trial was the first major trial of...
-
Jan 6, 2025 | 
digitalcommons.library.tmc.edu | Ambarish Pandey |Sanjiv Shah |Javed Butler |Dean Kellogg
KeywordsAging, Animals, Exercise Tolerance, Heart Failure, Diastolic, HumansAbstractExercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals.
-
Dec 1, 2024 | 
jacc.org | Wolfram Doehner |Stefan Anker |Javed Butler |Faiez Zannad
References1. "Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)". Am J Cardiol . 2014;114:1713-1721. 2. "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging". Circulation . 2003;107:1991-1997. 3.
-
Oct 30, 2024 | 
onlinelibrary.wiley.com | Yogesh N.V. Reddy |Javed Butler |Baylor Scott |Kevin J. Anstrom
Introduction Vericiguat, a soluble guanylate cyclase stimulator, is approved in many countries for the treatment of worsening heart failure (HF) with reduced ejection fraction (HFrEF).
-
Oct 22, 2024 | 
onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Rebecca Young |Javed Butler
Introduction The vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial demonstrated a 10% relative and 4.2 events/100 patient-years absolute risk reduction in a composite of heart failure (HF) hospitalization (HFH) or cardiovascular death relative to placebo in patients with high-risk HF.1 Differences in patient risk profiles add complexity to comparing the relative efficacy of vericiguat with other approved contemporary HF therapies.2 Thus, we...
-
Oct 16, 2024 | 
cfrjournal.com | Aleksandra Bykova |Clara Saldarriaga |Gianluigi Savarese |Javed Butler
Publications on heart failure (HF) with preserved ejection fraction (HFpEF) date back to 1984–85. Today, approximately 50% of all HF patients demonstrate preserved ejection fraction, and the prevalence of this condition continues to increases annually.1 This rise may be related to the growing incidence of comorbidities, such as hypertension, obesity, type 2 diabetes (T2D), coronary artery disease (CAD), chronic kidney disease (CKD), AF and obstructive sleep apnoea.
-
Oct 8, 2024 | 
ajmc.com | Javed Butler
OpinionVideoOctober 8, 2024Author(s): The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients. A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function. Significant improvements in myocardial performance indices were observed, indicating dapagliflozin's benefits beyond glycemic control.
